Cormorant Asset Management, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1583977) · Explore on the interactive board
Cormorant Asset Management, LP disclosed 50 US equity positions worth $2.0bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is PRAX at 11.0% of the reported book, followed by BBOT, PARABILIS MEDICINES INC. The top ten holdings are 59.2% of the book, and the portfolio behaves like about 22 equal-weight positions. Versus the prior filing it opened 13 new positions, added to 4, reduced 28 and exited 9. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Cormorant Asset Management, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 13 new, 4 added, 28 reduced, 9 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 11.0% | $214.3m | 640,000 | -28% | reduced |
| 2 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 7.0% | $136.2m | 17,878,594 | 0% | held | |
| 3 | PARABILIS MEDICINES INC | 6.5% | $126.3m | 4,615,612 | – | new | |
| 4 | RAPP RAPPORT THERAPEUTICS INC | 5.7% | $110.7m | 2,657,521 | -10% | reduced | |
| 5 | ERAS ERASCA INC | Healthcare | 5.6% | $109.9m | 6,000,000 | 3% | added |
| 6 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 5.2% | $102.0m | 2,510,000 | -23% | reduced |
| 7 | EYPT EYEPOINT INC | Healthcare | 5.1% | $100.1m | 7,000,000 | -15% | reduced |
| 8 | ALMS ALUMIS INC | Healthcare | 4.7% | $92.5m | 3,285,596 | -17% | reduced |
| 9 | ABVX ABIVAX SA | Healthcare | 4.6% | $90.0m | 675,000 | -11% | reduced |
| 10 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.7% | $73.1m | 750,000 | -21% | reduced |
| 11 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 3.2% | $63.2m | 900,000 | -15% | reduced |
| 12 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 3.2% | $62.4m | 3,205,433 | -28% | reduced |
| 13 | BIOA BIOAGE LABS INC | 3.0% | $58.6m | 2,390,605 | -17% | reduced | |
| 14 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 2.6% | $50.8m | 533,340 | 0% | held |
| 15 | ANL ADLAI NORTYE LTD | 2.3% | $45.7m | 3,978,229 | 37% | added | |
| 16 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.1% | $41.0m | 550,000 | -35% | reduced |
| 17 | TNGX TANGO THERAPEUTICS INC | Healthcare | 2.1% | $40.6m | 1,300,000 | -9% | reduced |
| 18 | BHVN BIOHAVEN LTD | Healthcare | 2.0% | $38.8m | 2,610,000 | 48% | added |
| 19 | AGOMAB THERAPEUTICS NV | 1.6% | $32.0m | 2,465,348 | 0% | held | |
| 20 | MBX MBX BIOSCIENCES INC | Healthcare | 1.6% | $30.4m | 550,000 | -51% | reduced |
| 21 | CLYM CLIMB BIO INC | Healthcare | 1.4% | $27.5m | 2,106,000 | – | new |
| 22 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.4% | $26.9m | 2,150,000 | -45% | reduced |
| 23 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 1.3% | $26.0m | 1,000,000 | -34% | reduced |
| 24 | PHVS PHARVARIS N V | Healthcare | 1.3% | $25.9m | 750,000 | -25% | reduced |
| 25 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.1% | $22.0m | 2,344,971 | 0% | held |
| 26 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.0% | $20.0m | 225,000 | – | new |
| 27 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.0% | $18.8m | 400,000 | – | new |
| 28 | NEWAMSTERDAM PHARMA COMPANY | 0.9% | $16.9m | 500,000 | -47% | reduced | |
| 29 | ROIV ROIVANT SCIENCES LTD | Healthcare | 0.9% | $16.8m | 475,000 | -37% | reduced |
| 30 | CABA CABALETTA BIO INC | Healthcare | 0.8% | $15.6m | 5,000,000 | -9% | reduced |
| 31 | HELIX ACQUISITION CORP III | 0.7% | $13.8m | 1,297,500 | 0% | held | |
| 32 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.7% | $13.3m | 50,000 | – | new |
| 33 | KAILERA THERAPEUTICS INC | 0.6% | $12.1m | 550,000 | – | new | |
| 34 | INSM INSMED INC | Healthcare | 0.4% | $8.0m | 75,000 | -61% | reduced |
| 35 | FTH FAETH THERAPEUTICS INC | 0.4% | $7.7m | 1,028,242 | 236% | added | |
| 36 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.4% | $7.6m | 150,000 | – | new |
| 37 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 0.3% | $6.3m | 100,000 | -56% | reduced |
| 38 | IBIO IBIO INC | 0.3% | $6.2m | 3,570,000 | – | new | |
| 39 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 0.2% | $4.7m | 125,000 | -50% | reduced | |
| 40 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.2% | $4.6m | 175,000 | -61% | reduced |
| 41 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.2% | $4.1m | 50,000 | -50% | reduced |
| 42 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.2% | $4.0m | 75,000 | -57% | reduced |
| 43 | RESEARCH ALLIANCE CORP III | 0.2% | $4.0m | 370,000 | – | new | |
| 44 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.2% | $3.9m | 100,000 | -50% | reduced |
| 45 | ALT ALTIMMUNE INC | Healthcare | 0.2% | $3.8m | 1,250,000 | – | new |
| 46 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 0.2% | $3.6m | 200,000 | -43% | reduced |
| 47 | ODYSSEY THERAPEUTICS INC | 0.2% | $3.3m | 175,000 | – | new | |
| 48 | PCVX VAXCYTE INC | Healthcare | 0.1% | $2.9m | 50,000 | -50% | reduced |
| 49 | BOLD BOUNDLESS BIO INC | 0.1% | $2.5m | 1,000,000 | – | new | |
| 50 | QUINCE THERAPEUTICS INC | 0.0% | $100.0k | 5,498 | – | new |
What did Cormorant Asset Management, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| CNTA CENTESSA PHARMACEUTICALS PLC | 32.0% | $41.7m |
| MAZE MAZE THERAPEUTICS INC | 17.2% | $22.4m |
| ASND ASCENDIS PHARMA A/S | 16.7% | $21.7m |
| 430 TERNS PHARMACEUTICALS INC | 12.1% | $15.8m |
| ZURA ZURA BIO LTD | 6.6% | $8.6m |
| AXSM AXSOME THERAPEUTICS INC. | 6.5% | $8.5m |
| GLUE MONTE ROSA THERAPEUTICS INC | 5.1% | $6.6m |
| RLYB RALLYBIO CORP | 2.8% | $3.6m |
| CNTX CONTEXT THERAPEUTICS INC | 1.1% | $1.4m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 70.2% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Cormorant Asset Management, LP's portfolio?
Across every quarter Cormorant Asset Management, LP has filed, its median largest position is 12.7% of the book and its median top-ten weight is 59.2%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 8.0 completed holding spells, the median lasted 1.0 quarters; 50.0 positions are still open and their final length is unknown.